GeneralPublished June 29, 2010 at 12:52 am No Comments
One of the Chinese drug companies I’ve been following for almost a year is Sinobiopharma, Inc. (OTC:SNBP).
by J. Christoph Amberger
Baltimore, MD: Last June, in a small ceremony in Guangzhou, China, U.S. and Chinese officials signed three agreements that will change the face of the global pharma industry. At face value, it was the most boring
read more..
GeneralPublished June 29, 2010 at 12:52 am No Comments
It’s Keynesian economics at its finest: Govenment CAN spend a sector out of a slump… as long as it keeps paying people to spend! Could home builders like Beazer Homes (NYSE:BZH) and Hovnanian Enterprises (NYSE:HOV) be rising on anticipated subsidies?
By J. Christoph Amberger
Baltimore, MD: Let’s hear it for government spending the economy out of recession!
Sales of
read more..
GeneralPublished June 29, 2010 at 12:52 am No Comments
The Dow’s experienced the steepest drop since Feb. 2009. What lies ahead?
by J. Christoph Amberger
Baltimore, MD: The weeks started on such a promising note I was fantasizing about a Dow 11,000, giddy at the prospects that Brown would do for you what he did for re-establishing a semblance of balance of power in the United
read more..
GeneralPublished June 29, 2010 at 12:52 am No Comments
The list reads like wind chills in Chicago on a cold winter day: Coeur d’Alene Mines Corporation (NYSE:CDE), Silver Wheaton Corp. (NYSE:SLW), Alto Group Holdings Inc. (OTC:ALTO), Hecla Mining Company (NYSE:HL), Endeavour Silver Corp. (AMEX:EXK) all close down dramatically for a second day. What to do now?
by J. Christoph Amberger
Baltimore, MD: The price decline in
read more..
GeneralPublished June 28, 2010 at 12:46 am No Comments
One of the Chinese drug companies I’ve been following for almost a year is Sinobiopharma, Inc. (OTC:SNBP).
by J. Christoph Amberger
Baltimore, MD: Last June, in a small ceremony in Guangzhou, China, U.S. and Chinese officials signed three agreements that will change the face of the global pharma industry. At face value, it was the most boring
read more..
GeneralPublished June 28, 2010 at 12:46 am 1 Comment
It’s Keynesian economics at its finest: Govenment CAN spend a sector out of a slump… as long as it keeps paying people to spend! Could home builders like Beazer Homes (NYSE:BZH) and Hovnanian Enterprises (NYSE:HOV) be rising on anticipated subsidies?
By J. Christoph Amberger
Baltimore, MD: Let’s hear it for government spending the economy out of recession!
Sales of
read more..
GeneralPublished June 28, 2010 at 12:46 am No Comments
The Dow’s experienced the steepest drop since Feb. 2009. What lies ahead?
by J. Christoph Amberger
Baltimore, MD: The weeks started on such a promising note I was fantasizing about a Dow 11,000, giddy at the prospects that Brown would do for you what he did for re-establishing a semblance of balance of power in the United
read more..
GeneralPublished June 28, 2010 at 12:46 am No Comments
The list reads like wind chills in Chicago on a cold winter day: Coeur d’Alene Mines Corporation (NYSE:CDE), Silver Wheaton Corp. (NYSE:SLW), Alto Group Holdings Inc. (OTC:ALTO), Hecla Mining Company (NYSE:HL), Endeavour Silver Corp. (AMEX:EXK) all close down dramatically for a second day. What to do now?
by J. Christoph Amberger
Baltimore, MD: The price decline in
read more..
GeneralPublished June 2, 2010 at 1:46 am No Comments
Internet advertising revenue in the U.S. reached $5.9 billion in the first quarter of 2010, representing a 7.5 percent increase over the same period in 2009.
The numbers come from the latest analysis released by the Interactive Advertising Bureau (IAB) and PricewaterhouseCoopers (PwC). The figures mark the highest first quarter revenue level ever for the industry.
read more..
GeneralPublished May 24, 2010 at 8:22 pm No Comments
One of the Chinese drug companies I’ve been following for almost a year is Sinobiopharma, Inc. (OTC:SNBP).
by J. Christoph Amberger
Baltimore, MD: Last June, in a small ceremony in Guangzhou, China, U.S. and Chinese officials signed three agreements that will change the face of the global pharma industry. At face value, it was the most boring
read more..